Vulnerability in Apollo Pharmacy Blood Glucose Monitoring System (Model No. Apg-01 Bt)

CVE-2026-50034

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

Published · last modified .

CVSS v3 metric

CVSS v3 base score 6.5 (Medium). Vector: CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N.

EPSS exploit prediction

EPSS: 0.002 (10.0th percentile), scored .

Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 10th percentile — 10.0% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS trend (30 days)EPSS over the last 30 days for CVE-2026-50034: held from 0.002 to 0.002.

EPSS over last 30 days · oldest: 0.002 · newest: 0.002 · change: 0.000

Affected products

Weakness classification (CWE)

References

Frequently asked questions

What is CVE-2026-50034?
CVE-2026-50034 is a medium-severity vulnerability in Apollo Pharmacy Blood Glucose Monitoring System (Model No. Apg-01 Bt), classified under Cleartext Transmission of Sensitive Information. CVSS score: 6.5/10. Published 2026-06-19.
How severe is CVE-2026-50034?
Medium severity. CVSS v3 base score is 6.5 out of 10.